INTRODUCTION
============

Behcet disease is a chronic and systemic vasculitis of unknown origin affecting blood vessels of any size \[[@b1-kjim-2016-367]\]. Clinical manifestation of Behcet disease is very diverse, and involves the mucous membranes, eyes, blood vessels, joints, gastrointestinal tract, urogenital, respiratory, nervous system, etc. These complex and varied symptoms are continuously in a cycle of remissions and recurrences, resulting in difficulty to predict progress of the disease. These problems also cause restrictions on personal life, and many patients have associated psychiatric problems.

Various studies concerning sleep quality and Behcet disease have been done. Turkish studies reported the sleep quality in Behcet disease is very poor, and restless legs syndrome, fatigue, depression, anxiety, and activity of Behcet disease could affect to the quality of life \[[@b2-kjim-2016-367]\]. Other studies report that fibromyalgia is a commonly occurring syndrome in Behcet disease, and showed a significant relationship with depression and anxiety; however, they were not related with disease activity \[[@b3-kjim-2016-367],[@b4-kjim-2016-367]\].

Previously, we compared and evaluated the sleep quality, quality of life, depression, and disease activity in rheumatoid arthritis (RA) patients \[[@b5-kjim-2016-367]\] and ankylosing spondylitis patients \[[@b6-kjim-2016-367]\]. A significant relationship between disease activity and sleep quality was observed. However, to date, there have been limited studies regarding sleep quality, quality of life, and depression in Behcet disease patients for Korean population. Extrapolating that Behcet disease, a kind of RA, also affects the sleep quality, it is considered a meaningful study to compare and analyze the relationship between disease activity and sleep quality, quality of life, and depression in Korean population of Behcet disease patients.

METHODS
=======

Study population
----------------

Study participants were enrolled from February 2014 to July 2015. A total of 100 patients with Behcet disease, who visited two selected rheumatology clinic centers in Korea, were enrolled.

Inclusion criteria for patient group were adults 19 years or more, and who met the diagnostic criteria proposed at the International Study Group of Behcet disease \[[@b7-kjim-2016-367]\]. Exclusion criteria were patients who were uneducated and unable to answer the questionnaire, had a low mental aptitude, a medical disease history like malignant tumor or infection, or who were suspected to be drug addicts (including sleeping pills or alcohols).

Ethics statement
----------------

This study was approved by Institutional Review Board (IRB) at the university hospital where the study was conducted. (IRB number: 2014-07-017).

Assessment of clinical variables
--------------------------------

Along with the questionnaire, face-to-face interviews were conducted with the Behcet disease patients. Age, gender, body mass index, other associated disease history, and the kind, frequency of smoking and caffeine consumptions, social-economic status, and demographic information (such as accompanying residents) were investigated. Sleep quality, quality of life (QoL), depression, fibromyalgia, and disease activity of Behcet disease were also scrutinized from the questionnaire. Through the medical records, additional investigation were conducted, such as blood test for C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), disease duration, and medical history associated with Behcet disease.

Assessment of sleep quality
---------------------------

Quality of sleep was evaluated using the Korean version of the Pittsburgh sleep quality index (PSQI). PSQI consists of questionnaires regarding sleep habits over the past 1 month, and is a useful test to evaluate the sleep quality.

It contains seven subsections: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each of these components has a range of 0 to 3 points, with a total adding up in the ranges 0 to 21 points. Higher scores indicate poor sleep quality; when total score is more than 9, they are defined as the poor sleeper group \[[@b8-kjim-2016-367]\].

Assessment of life quality
--------------------------

QoL was evaluated using the Korean version of the Leeds Behcet disease quality of life measure (BDQoL). This tool consists of 30 components regarding QoL with Yes/No answer. Each component has a range of 0 to 1 points, and the lower scores indicate worse QoL as based on a maximum of 30 points \[[@b9-kjim-2016-367]\].

Assessment of depression
------------------------

Korean version of the Beck depression inventory second edition (BDI-2) was used to evaluate the degree of depression.

BDI-2 consists of 21 multiple-choice self-report inventory, with points ranging from 0 to 3. By adding the scores of each components, a range from 0 to 63 points are assessed. Higher scores indicate severe depression, and 20 points are defined as cut-off point for depression \[[@b10-kjim-2016-367]\].

Assessment of Behcet disease activity
-------------------------------------

Behcet disease current activity form (BDCAF) was evaluated as an indicator of Behcet disease activity. To assess the disease activity, we used the English version of BDCAF, first designed in 1999 and amended once in 2006.

Depending on the presence of symptom which patients complained of during the past 1 month, the score is measured as 0 to 1 points, with the total adding up in the range 0 to 12. Each component consists of headache, oral ulcer, genital ulcer, erythema, skin pustule, arthritis, arthralgia, nausea/vomiting/abdominal pain, diarrhea or frank blood per rectum, new symptoms in eye, new symptoms in nervous system, and new symptoms in major vessels. When the total score is higher than 5 points, it is defined as the high active Behcet disease patients group \[[@b11-kjim-2016-367]\].

Assessment of fibromyalgia and pain
-----------------------------------

Fibromyalgia is a chronic systemic pain disorder, and it usually accompanies chronic fatigue, sleep disturbance, depression, etc. It is usually associated with inflammatory autoimmune disease such as RA, systemic lupus erythematous, or Behcet disease. From the fibromyalgia questionnaire survey, the degree of fibromyalgia was investigated, and the degree of pain was measured by visual analogue scale (VAS), which is the patient global assessment for Behcet disease, and indicated from 0 to 100 score for the extent of patients' feeling.

Statistical analysis
--------------------

The statistical program SPSS version 20.0 (IBM Co., Armonk, NY, USA) was used for data processing and statistical analysis. Patients were presented as number and percentage for each assessment, and continuous variable results were presented as medium values and interquartile using a *t* test. According to the presence of Behcet disease activity and sleep disturbance, variables were compared in the two groups, and Mann-Whitney *U* test was used for analysis. By setting the Behcet disease activity as a continuous variable, Spearman correlation coefficients were used to examine the correlations between the factors which associated with Behcet disease activity such as BDI-2, BDQoL, total PSQI, and subsection PSQI. Logistic regression analysis was performed to detect the independent risk factors for the occurrence of sleep disturbance. In the analysis, each factor was an independent variable, and the total PSQI was a dependent variable. All the results with *p* value less than 0.05 considered to be significant.

RESULTS
=======

Demographic and clinical characteristics of Behcet patients
-----------------------------------------------------------

The median age of Behcet disease patients was 51 years, with a higher percentage reported in women (69%). Among the favorite foods, caffeine consumption was 86%, alcohol 28%, and smoking 13%. Economic activity and residential status for the patients were also investigated. The proportion of unemployed worker, part time worker, and full time worker was 45%, 11%, and 44%, respectively. As per the living status, 9% were living alone and 91% were living with family. In all, 20% had other associated disease, including hypertension, osteoarthritis, thyroid disease (hypothyroidism and hyperthyroidism), diabetes, chronic obstructive pulmonary disease, and atrial fibrillation. The average duration of Behcet disease was 77.5 months, and the average amount and period of steroid use were 2.5 mg and 11 months, respectively. The median of CRP and ESR were within the normal range of 0.1 and 15.0, respectively. Amongst the 100 patients, poor sleeper group were 42 patients (42%) and the patients who met the criteria for fibromyalgia were 28 ([Table 1](#t1-kjim-2016-367){ref-type="table"}).

Comparison between good sleeper and poor sleeper group
------------------------------------------------------

In the poor sleeper group (PSQI ≥ 9), the percentage of women and fibromyalgia were significantly higher at 34% and 24%, respectively (*p* = 0.004, *p* \< 0.001). BDCAF, BDI-2, pain VAS were significantly higher in the group with sleep disturbance (*p* = 0.022, *p* = 0.005, *p* \< 0.001, respectively) and BDQoL was lower (*p* \< 0.001). Among the BDCAF subsection, the frequency of genital ulcer was significantly higher in the group with poor sleep quality (*p* = 0.01). There were no significant differences between the two groups with regards to CRP, ESR, drug consumption, disease duration, age, living status, and economic activity sections ([Table 2](#t2-kjim-2016-367){ref-type="table"}).

Comparison according to Behcet disease activity
-----------------------------------------------

The proportion of high disease activity in Behcet disease patients group (BDCAF \> 5) was 17%, and the duration of disease and prednisolone used were significantly shorter (*p* = 0.008, *p* = 0.032). The proportion with fibromyalgia in patients, pain VAS, and BDI-2 were significantly higher (*p* \< 0.001, *p* = 0.005, *p* = 0.008, respectively), and the BDQoL was significantly lower (*p* = 0.04). In the analysis of total PSQI and subsection PSQI, daytime dysfunction was significantly higher with higher disease activity (*p* = 0.03) ([Table 3](#t3-kjim-2016-367){ref-type="table"}).

Correlation and regression analysis
-----------------------------------

From the results of Spearman analysis, significant correlation is observed between total PSQI and VAS, BDI-2, and BDQoL, with the correlation coefficients being 0.35, 0.52, and --0.45, respectively (*p* \< 0.01). BDCAF showed significant correlation, having a correlation coefficient of 0.23 (*p* \< 0.05). Sleep disturbance and daytime dysfunction also showed significant correlation with the VAS, BDI-2, BDQoL, and BDCAF. Use of sleep medication significantly correlated with the BDI-2 and BDQoL. The other factors for PSQI, which include sleep latency, habitual sleep efficiency, sleep duration, and subjective sleep quality, were positively correlated to VAS and BDI- 2, and negatively to BDQoL. In addition, the patient's age, duration of disease, ESR, CRP did not show statistically significant correlation with PSQI ([Table 4](#t4-kjim-2016-367){ref-type="table"}).

Through logistic regression analysis, sex, pain VAS score, fibromyalgia, BDI-2, and BDQoL were set as independent variables. Regression analysis showed that BDCAF was significant risk factors for sleep disturbance ([Table 5](#t5-kjim-2016-367){ref-type="table"}).

DISSCUSION
==========

According to our study, the group with sleep disturbance had a higher degree of pain, depression, and disease activity, with significantly lower quality of life. Recently, along with the aging of the population and the increasing the number of patients who are suffering from chronic diseases, modern healthcare reveals that the mental and social health are closely associated with physical health, and their importance is gradually increasing. In psychosocial health, sleep quality, QoL, and depression could be important factors. The frequency of patients with sleep disturbances in Korean population is known to be about 5% \[[@b12-kjim-2016-367]\], and it has been reported that sleep disturbance is reported in various chronic disease patients, such as chronic renal failure \[[@b13-kjim-2016-367]\] and restless legs syndrome \[[@b14-kjim-2016-367]\]. Rheumatoid disease is one of chronic diseases; various studies done worldwide have reported that sleep disturbance is a common associate in RA \[[@b5-kjim-2016-367],[@b15-kjim-2016-367]\] or ankylosing spondylitis patients \[[@b6-kjim-2016-367]\]. The foreign researches also studied the relationship between Behcet disease and sleep disturbance. However, the results did not indicate a significant impact on sleep quality with respect to the disease activity and severity; the studies mainly focused on comparing the sleep quality in Behcet disease patients and healthy volunteers \[[@b10-kjim-2016-367]-[@b12-kjim-2016-367]\]. Also, since the domestic research on the sleep quality of Korean Behcet disease is limited, we planned to undertake this study.

Behcet disease is a chronic and systemic disorder affecting multiple organs with a generalized angiitis of arteries and veins \[[@b1-kjim-2016-367]\], and the cause was not clearly revealed until now. The progression of Behcet disease is unpredictable as the remissions and recurrences appear as a continuous cycle. Mental stress is a known reason which causes worsening of the disease, and the symptoms may appear as deterioration of joint pain and eye symptoms \[[@b16-kjim-2016-367]\]. Yazmalar et al. \[[@b17-kjim-2016-367]\] reported the relationship between sleep quality in Behcet disease patients, and genital ulcers or arthritis. This study also demonstrated the score of BDCAF which showed the disease activity was higher in poor sleeper group, and the frequency of genital ulcers was higher among the 12 subsections. These symptoms from the deterioration of Behcet disease accompanied pain to the patient. In our study, the disease activity and pain showed significant positive correlations in most of PSQI sections.

Depression is the most common mental disorder in general adults, and it is well known to be accompanied by various chronic diseases. Some domestic studies have reported up to 50.9% of RA patients have accompanying depression. In our study, the proportion of patients with depression was 46%. Based on the previous studies that depression and sleep disturbance have positive correlations in general population or other patients, we included depression as an important risk factor. Yazmalar et al. \[[@b17-kjim-2016-367]\] evaluated the degree of depression in Behcet disease patients using Hospital Anxiety and Depression Scale, and reported total PSQI and seven subsections had significant correlation with depression. Similar to previous studies, our study showed significantly higher BDI-2 score in poor sleeper group, and significant correlations in total PSQI and every subsection. Also, the higher disease activity group showed a significantly higher BDI-2 score.

Pain, depression and sleep disorders due to chronic disease were eventually results in lowering the quality of life. Ertam et al. \[[@b18-kjim-2016-367]\] investigated the QoL of Behcet disease patients using SF-36 and WHOQOL-100. They reported that their QoL deteriorated by activity of disease, and arthritis, ocular symptoms, or major vessels, and the disorder had a significant correlation with the degradation of QoL.

A variety of tools have been developed for evaluating the quality of life, and the Leeds BDQoL as self-testing format and developed by Gilworth et al. \[[@b4-kjim-2016-367]\] is effectively used to evaluate the QoL of Behcet disease patients. In our study results from BDQoL, QoL deteriorated in the sleep disturbance group and high disease activity group, and had a significant correlation with every section of PSQI. This suggests that the QoL of the patient can be improved by maintaining low the disease activity of Behcet disease.

There are various limitations to this study. Firstly, the study was only carried out for total of 100 patients enrolled in the university hospital outpatient department, and a small number of cases cannot represent the whole Behcet disease. Secondly, the average inflammation levels which could objectively compare the disease itself, such as CRP and ESR, were 0.1 as normal ranges, and drugs consumed, including prednisolone, did not vary. Third, until recently, the standard to divide the presence or absence of disease activity of Behcet disease was not generally established. A criteria to decide disease activity of Behcet disease is yet to be established, similar to DAS-28 (Disease Activity Score 28) for disease activity of RA, or BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) to assess for disease activity of ankylosing spondylitis. It will be easier to plan the various studies more precisely and segmentally, once such a criteria is established. However, this study is significant to study the sleep disturbance, QoL, depression, and the other related factors in Korean Behcet disease patients for the first time and reveal their correlations.

KEY MESSAGE
===========

1\. Low sleep quality is related with high disease activity, depression and low quality of life in Korean Behcet disease patients.

2\. Better disease control will improve the sleep quality of the patients.
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###### 

Demographic and clinical characteristics of Behcet disease patients

  Variable                            Value
  ----------------------------------- --------------------
  Mean age, yr                        51 (44.5--56.0)
  Female sex                          69
  Mean BMI, kg/m^2^                   22.4 (20.5--24.4)
  Employment status                   
   None                               45
   Part time                          11
   Full time                          44
  Living circumstances                
   Alone                              9
   Partner                            91
  Disease duration, mon               77.5 (24.0--136.0)
  Concurrent consumptions             
   Caffeine                           89
   Alcohol                            28
  Comorbidities                       
   Hypertension                       13
   Osteoarthritis                     12
   Diabetes mellitus                  6
   Thyroid disease                    6
   Atrial flutter                     1
   Chronic obstructive lung disease   1
  Mean ESR, mm/hr                     15.0 (7.0--25.0)
  Mean CRP, mg/dL                     0.1 (0.0--0.3)
  Mean prednisolone dose, mg          2.5 (2.0--5.0)
  Mean prednisolone duration, mon     11.0 (8.0--22.0)
  Current BD medication               
   Prednisolone                       90
   Methotrexate                       5
   Hydroxyquinolone                   7
   Sulfasalazine                      18
   Mizoribine                         3
   Tacrolimus                         1
   Azathioprine                       13
   Cyclosporine                       6
  Poor sleepers                       42
  Mean PSQI score                     7.0 (4.5--11.5)
  Fibromyalgia                        28
  Mean VAS score                      30.0 (20.0--55.0)
  Mean BDCAF                          3.0 (2.0--4.0)
  Active BD patients                  17

Values are presented as percentage or median (range).

BMI, body mass index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BD, Behcet disease; PSQI, Pittsburgh sleep quality index; VAS, visual analogue scale; BDCAF, Behcet disease current activity form.

###### 

Comparison between good sleeper and poor sleeper group

  Variable                       Good sleeper (n = 58)   Poor sleeper (n = 42)   *p* value
  ------------------------------ ----------------------- ----------------------- ------------------------------------------------------
  Female sex                     35 (60.3)               34 (81.0)               0.004^[a](#tfn1-kjim-2016-367){ref-type="table-fn"}^
  Age, yr                        51.0 (44.0--57.0)       51.0 (46.0--55.0)       0.507
  BMI, kg/m^2^                   23.0 (21.6--24.3)       22.0 (20.4--24.4)       0.349
  Disease duration, mon          79.0 (24.0--169.0)      73.0 (30.0--131.0)      0.655
  ESR, mm/hr                     14.0 (5.0--24.0)        16.5 (10.0--27.0)       0.206
  CRP, mg/mL                     0.1 (0.0--0.5)          0.1 (0.0--0.2)          0.675
  Prednisolone dose, mg          2.5 (2.0--5.0)          3.2 (2.0--5.0)          0.889
  Prednisolone duration, mon     10.0 (7.0--21.0)        14.0 (9.0--22.0)        0.166
  VAS                            30.0 (10.0--50.0)       50.0 (30.0--70.0)       0.005^[a](#tfn1-kjim-2016-367){ref-type="table-fn"}^
  Fibromyalgia                   4 (3.0)                 24 (40.3)               0.000^[a](#tfn1-kjim-2016-367){ref-type="table-fn"}^
  BDI-2                          8.0 (4.0--13.0)         19.0 (9.0--23.0)        0.000^[a](#tfn1-kjim-2016-367){ref-type="table-fn"}^
  BDQoL                          25 (20.0--28.0)         18.5 (13.0--23.0)       0.000^[a](#tfn1-kjim-2016-367){ref-type="table-fn"}^
  BDCAF                                                                          
   Total score                   2.0 (1.0--4.0)          3.0 (2.0--4.0)          0.022^[b](#tfn2-kjim-2016-367){ref-type="table-fn"}^
   Headache                      11 (19)                 16 (38.1)               0.058
   Oral ulcer                    41 (70.7)               34 (81)                 0.349
   Genital ulcer                 7 (12.1)                15 (35.7)               0.010^[b](#tfn2-kjim-2016-367){ref-type="table-fn"}^
   Erythema                      12 (20.7)               7 (16.7)                0.804
   Skin pustule                  7 (12.1)                5 (11.9)                1.000
   Arthritis                     16 (27.6)               15 (35.7)               0.517
   Arthralgia                    9 (27.3)                33 (49.3)               0.445
   Eye symptoms                  9 (15.5)                9 (21.4)                0.620
   Nausea/Vomit/Abdominal pain   10 (17.2)               7 (16.7)                1.000
   Diarrhea/Blood per rectum     7 (12.1)                1 (2.4)                 0.165
   Major vessel involvement      2 (3.4)                 6 (14.3)                0.110
   Nerve involvement             8 (13.8)                9 (21.4)                0.463

Values are presented as number (%) or median (range).

BMI, body mass index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; VAS, visual analogue scale; BDI-2, Korean version of the Beck depression inventory second edition; BDQoL, Korean version of the Leeds Behcet disease quality of life measure; BDCAF, Behcet disease current activity form.

*p*\< 0.01.

*p*\< 0.05.

###### 

Comparison according to Behcet disease activity

  Variable                     BDCAF ≤ 5 (n = 83)   BDCAF \> 5 (n = 17)   *p* value
  ---------------------------- -------------------- --------------------- ------------------------------------------------------
  Age, yr                      51.0 (44.0--56.0)    49.0 (46.0--56.0)     0.810
  BMI, kg/m^2^                 22.7 (20.7--24.4)    21.6 (20.3--25.6)     0.330
  Employment status                                                       0.390
   None                        35 (42.2)            10 (58.8)             
   Part time                   9 (10.8)             2 (11.8)              
   Full time                   39 (47.0)            5 (29.4)              
  Living circumstances                                                    0.360
   Alone                       6 (7.2)              3 (17.6)              
   Partner                     77 (91.8)            14 (82.4)             
  Caffeine                     28 (90.3)            61 (88.4)             0.100
  Alcohol                      15 (48.4)            13 (18.8)             0.080
  Smoking                      12 (14.5)            1 (5.9)               0.570
  Disease duration, mon        90.0 (35.5--147.0)   30.0 (16.0--55.0)     0.008^[a](#tfn3-kjim-2016-367){ref-type="table-fn"}^
  Prednisolone dose, mg        2.5 (2.0--4.5)       4.0 (2.0--7.5)        0.160
  Prednisolone duration, mon   12.0 (8.0--24.0)     9.0 (8.0--10.0)       0.030^[b](#tfn4-kjim-2016-367){ref-type="table-fn"}^
  ESR, mm/hr                   15.0 (7.0--25.5)     16.0 (6.0--22.0)      0.650
  CRP, mg/dL                   0.1 (0.0--0.3)       0.0 (0.0--0.1)        0.020^[b](#tfn4-kjim-2016-367){ref-type="table-fn"}^
  PSQI total score             7.0 (4.0--11.0)      10.0 (6.0--12.0)      0.114
   Sleep latency               1.46 (0.2--2.6)      1.88 (0.8--3.2)       0.170
   Sleep duration              1.57 (0.39--2.6)     1.65 (0.0--2.0)       0.770
   Sleep efficiency            0.98 (0.0--2.8)      0.59 (0.0--2.0)       0.230
   Sleep disturbance           1.17 (0.3--2.3)      1.41 (0.6--2.2)       0.160
   Sleep medication            0.37 (0.0--1.3)      0.41 (0.0--3.0)       0.880
   Sleep quality               1.46 (0.1--2.3)      1.82 (0.8--2.7)       0.110
   Daytime dysfunction         1.02 (0.2--2.0)      1.71 (0.1--2.9)       0.030^[b](#tfn4-kjim-2016-367){ref-type="table-fn"}^
  VAS                          30.0 (10.0--50.0)    50.0 (30.0--80.0)     0.005^[a](#tfn3-kjim-2016-367){ref-type="table-fn"}^
  BDI-2                        10.0 (5.0--18.0)     19.0 (15.0--24.0)     0.008^[a](#tfn3-kjim-2016-367){ref-type="table-fn"}^
  BDQOL                        23.0 (16.5--27.0)    18.0 (14.0--24.0)     0.040^[b](#tfn4-kjim-2016-367){ref-type="table-fn"}^

Values are presented as number (%) or median (range).

BDCAF, Behcet disease current activity form; BMI, body mass index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PSQI, Pittsburgh sleep quality index; VAS, visual analogue scale; BDI-2, Korean version of the Beck depression inventory second edition; BDQoL, Korean version of the Leeds Behcet disease quality of life measure.

*p*\< 0.01.

*p*\< 0.05.

###### 

Correlation coefficients between components of PSQI and demographic and disease-related variables

  Variable           Total PSQI                                              Sleep latency                                           Sleep efficiency                                        Sleep duration                                          Sleep disturbance                                       Sleep medication                                       Daytime dysfunction                                    Sleep quality
  ------------------ ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------ -------------------------------------------------------
  Age                0.02                                                    --0.07                                                  --0.120                                                 --0.049                                                 --0.156                                                 --0.036                                                --0.074                                                --0.045
  Disease duration   --0.09                                                  --0.02                                                  --0.035                                                 --0.060                                                 --0.145                                                 --0.115                                                --0.012                                                --0.103
  CRP                --0.105                                                 --0.137                                                 --0.003                                                 --0.019                                                 --0.095                                                 --0.028                                                --0.132                                                --0.005
  ESR                0.079                                                   --0.002                                                 --0.130                                                 --0.019                                                 --0.068                                                 --0.090                                                --0.065                                                --0.181
  VAS                0.35^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^     0.21^[b](#tfn6-kjim-2016-367){ref-type="table-fn"}^     0.28^[b](#tfn6-kjim-2016-367){ref-type="table-fn"}^     0.25^[b](#tfn6-kjim-2016-367){ref-type="table-fn"}^     0.28^[b](#tfn6-kjim-2016-367){ref-type="table-fn"}^     0.03                                                   0.28^[b](#tfn6-kjim-2016-367){ref-type="table-fn"}^    0.36^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^
  BDI-2              0.52^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^     0.43^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^     0.34^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^     0.36^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^     0.29^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^     0.23^[b](#tfn6-kjim-2016-367){ref-type="table-fn"}^    0.28^[b](#tfn6-kjim-2016-367){ref-type="table-fn"}^    0.5^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^
  BDQoL              --0.45^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^   --0.36^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^   --0.33^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^   --0.29^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^   --0.31^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^   --0.2^[b](#tfn6-kjim-2016-367){ref-type="table-fn"}^   --0.3^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^   --0.39^[a](#tfn5-kjim-2016-367){ref-type="table-fn"}^
  BDCAF              0.23^[b](#tfn6-kjim-2016-367){ref-type="table-fn"}^     0.17                                                    0.09                                                    0.12                                                    0.21^[b](#tfn6-kjim-2016-367){ref-type="table-fn"}^     0.1                                                    0.26^[b](#tfn6-kjim-2016-367){ref-type="table-fn"}^    0.17

PSQI, Pittsburgh sleep quality index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; VAS, visual analogue scale; BDI-2, Korean version of the Beck depression inventory second edition; BDQoL, Korean version of the Leeds Behcet disease quality of life measure; BDCAF, Behcet disease current activity form.

*p*\<0.01.

*p*\<0.05.

###### 

Univariate logistic regression analysis between PSQI and BDCAF as a continuous variable

  Variable   PSQI                  
  ---------- --------------------- -------
  BDCAF      1.34 (1.007--1.776)   0.045

PSQI, Pittsburgh sleep quality index; BDCAF, Behcet disease current activity form; OR, odds ratio; CI, confidence interval.

[^1]: These authors contributed equally to this work.
